Login to Your Account



Amgen, UCB tout data on osteoporosis drug's benefit in men

By Michael Fitzhugh
Staff Writer

Monday, March 21, 2016

Amgen Inc. and its partner UCB SA reported that the sclerostin inhibitor romosozumab met its primary endpoint in a pivotal phase III study, called Bridge, providing men with osteoporosis with a statistically significant increase in bone mineral density at the lumbar spine vs. placebo at 12 months.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription